Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

This study is looking for adults aged 18 or older who have a specific type of gut neuroendocrine tumour that has been confirmed by tests. You must have already completed four cycles of Lutathera treatment in the past, and your cancer should have been stable for at least 12 months after that first treatment.

Now, your cancer must be showing signs of growing again (this could be from scans or other tests). The decision to consider more Lutathera treatment must have been discussed and approved by a specialist cancer team. You need to be generally well enough to participate, with a good outlook for your health for at least the next six months.

Your cancer cells must also show up clearly on special scans that look for certain markers (like Gallium-68 or Indium-111 scans). You must have cancer that can be measured on regular scans, and your blood tests for bone marrow health (like haemoglobin, white blood cells, and platelets) need to be within a healthy range. If you are a woman who could become pregnant, you'll need a negative pregnancy test and to use effective contraception during and for six months after the study.

If you join this study, you will either receive two extra doses of Lutathera or be carefully monitored, depending on which group you are assigned to. The Lutathera doses are typically given every eight weeks. This study builds on current practices where you would have already received at least two additional cycles of Lutathera after your initial four cycles. You will have regular doctor's visits, blood tests, and scans to check how your cancer is responding and to monitor for any side effects. The total duration of your participation will depend on how your cancer responds to treatment and how long the study needs to follow your progress.